Does the media refer more to MDGL or QURE?

In the previous week, uniQure had 10 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 35 mentions for uniQure and 25 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.84 beat uniQure's score of -0.04 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive uniQure 8 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has higher valuation & earnings, QURE or ABVX?

uniQure has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio uniQure $16.10M 187.99 -$198.97M -$4.01 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is QURE or ABVX more profitable?

Abivax has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Abivax's return on equity of -99.02% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,350.73% -111.96% -29.01% Abivax N/A -99.02% -70.26%

Does the media favor QURE or ABVX?

In the previous week, uniQure had 22 more articles in the media than Abivax. MarketBeat recorded 35 mentions for uniQure and 13 mentions for Abivax. Abivax's average media sentiment score of 1.41 beat uniQure's score of -0.04 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 8 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Abivax 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, QURE or KRYS?

Krystal Biotech has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio uniQure $16.10M 187.99 -$198.97M -$4.01 N/A Krystal Biotech $389.13M 25.84 $204.83M $7.48 45.60

Is QURE or KRYS more profitable?

Krystal Biotech has a net margin of 53.92% compared to uniQure's net margin of -1,350.73%. Krystal Biotech's return on equity of 19.25% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,350.73% -111.96% -29.01% Krystal Biotech 53.92% 19.25% 17.62%

Does the media prefer QURE or KRYS?

In the previous week, uniQure had 15 more articles in the media than Krystal Biotech. MarketBeat recorded 35 mentions for uniQure and 20 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.17 beat uniQure's score of -0.04 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 8 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Krystal Biotech 13 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SMMT or QURE?

In the previous week, uniQure had 22 more articles in the media than Summit Therapeutics. MarketBeat recorded 35 mentions for uniQure and 13 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.35 beat uniQure's score of -0.04 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral uniQure 8 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, QURE or CYTK?

uniQure has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio uniQure $16.10M 187.99 -$198.97M -$4.01 N/A Cytokinetics $105.82M 90.70 -$784.96M -$6.84 N/A

Is QURE or CYTK more profitable?

Cytokinetics has a net margin of -784.02% compared to uniQure's net margin of -1,350.73%. Cytokinetics' return on equity of 0.00% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,350.73% -111.96% -29.01% Cytokinetics -784.02% N/A -52.86%

Does the media favor QURE or CYTK?

In the previous week, uniQure had 12 more articles in the media than Cytokinetics. MarketBeat recorded 35 mentions for uniQure and 23 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.79 beat uniQure's score of -0.04 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 8 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Cytokinetics 14 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

uniQure (QURE) Competitors

$42.83 -0.80 (-1.83%)

As of 09:49 AM Eastern

Compare

QURE vs. MDGL, ABVX, KRYS, SMMT, and CYTK

Should you buy uniQure stock or one of its competitors? MarketBeat compares uniQure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with uniQure include Madrigal Pharmaceuticals (MDGL), Abivax (ABVX), Krystal Biotech (KRYS), Summit Therapeutics (SMMT), and Cytokinetics (CYTK). These companies are all part of the "biotechnology" industry.

How does uniQure compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Madrigal Pharmaceuticals has a beta of -1.01, suggesting that its stock price is 201% less volatile than the broader market. Comparatively, uniQure has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Madrigal Pharmaceuticals presently has a consensus price target of $688.20, suggesting a potential upside of 47.27%. uniQure has a consensus price target of $65.00, suggesting a potential upside of 48.98%. Given uniQure's higher possible upside, analysts plainly believe uniQure is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.72
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

uniQure has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	11.26	-$288.28M	-$12.89	N/A
uniQure	$16.10M	187.99	-$198.97M	-$4.01	N/A

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, uniQure had 10 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 35 mentions for uniQure and 25 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.84 beat uniQure's score of -0.04 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
uniQure	8 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Madrigal Pharmaceuticals has a net margin of -25.32% compared to uniQure's net margin of -1,350.73%. Madrigal Pharmaceuticals' return on equity of -56.65% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
uniQure	-1,350.73%	-111.96%	-29.01%

Summary

Madrigal Pharmaceuticals beats uniQure on 9 of the 16 factors compared between the two stocks.

How does uniQure compare to Abivax?

uniQure (NASDAQ:QURE) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

In the previous week, uniQure had 22 more articles in the media than Abivax. MarketBeat recorded 35 mentions for uniQure and 13 mentions for Abivax. Abivax's average media sentiment score of 1.41 beat uniQure's score of -0.04 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	8 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Abivax	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

uniQure has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Abivax has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Abivax has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Abivax's return on equity of -99.02% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Abivax	N/A	-99.02%	-70.26%

uniQure currently has a consensus price target of $65.00, suggesting a potential upside of 48.98%. Abivax has a consensus price target of $156.50, suggesting a potential upside of 25.28%. Given uniQure's higher possible upside, analysts clearly believe uniQure is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

78.8% of uniQure shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

uniQure has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	187.99	-$198.97M	-$4.01	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Summary

uniQure beats Abivax on 10 of the 14 factors compared between the two stocks.

How does uniQure compare to Krystal Biotech?

uniQure (NASDAQ:QURE) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

78.8% of uniQure shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Krystal Biotech has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	187.99	-$198.97M	-$4.01	N/A
Krystal Biotech	$389.13M	25.84	$204.83M	$7.48	45.60

Krystal Biotech has a net margin of 53.92% compared to uniQure's net margin of -1,350.73%. Krystal Biotech's return on equity of 19.25% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Krystal Biotech	53.92%	19.25%	17.62%

In the previous week, uniQure had 15 more articles in the media than Krystal Biotech. MarketBeat recorded 35 mentions for uniQure and 20 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.17 beat uniQure's score of -0.04 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	8 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Krystal Biotech	13 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

uniQure currently has a consensus price target of $65.00, suggesting a potential upside of 48.98%. Krystal Biotech has a consensus price target of $360.67, suggesting a potential upside of 5.73%. Given uniQure's higher possible upside, equities research analysts plainly believe uniQure is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

uniQure has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Summary

Krystal Biotech beats uniQure on 11 of the 16 factors compared between the two stocks.

How does uniQure compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Summit Therapeutics presently has a consensus price target of $26.15, suggesting a potential upside of 100.88%. uniQure has a consensus price target of $65.00, suggesting a potential upside of 48.98%. Given Summit Therapeutics' higher probable upside, equities analysts plainly believe Summit Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, uniQure had 22 more articles in the media than Summit Therapeutics. MarketBeat recorded 35 mentions for uniQure and 13 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.35 beat uniQure's score of -0.04 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
uniQure	8 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summit Therapeutics has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market. Comparatively, uniQure has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

uniQure has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
uniQure	$16.10M	187.99	-$198.97M	-$4.01	N/A

Summit Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. uniQure's return on equity of -111.96% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
uniQure	-1,350.73%	-111.96%	-29.01%

Summary

uniQure beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

How does uniQure compare to Cytokinetics?

uniQure (NASDAQ:QURE) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

78.8% of uniQure shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

uniQure presently has a consensus price target of $65.00, suggesting a potential upside of 48.98%. Cytokinetics has a consensus price target of $99.90, suggesting a potential upside of 29.52%. Given uniQure's higher possible upside, equities research analysts clearly believe uniQure is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95

uniQure has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	187.99	-$198.97M	-$4.01	N/A
Cytokinetics	$105.82M	90.70	-$784.96M	-$6.84	N/A

Cytokinetics has a net margin of -784.02% compared to uniQure's net margin of -1,350.73%. Cytokinetics' return on equity of 0.00% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Cytokinetics	-784.02%	N/A	-52.86%

uniQure has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

In the previous week, uniQure had 12 more articles in the media than Cytokinetics. MarketBeat recorded 35 mentions for uniQure and 23 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.79 beat uniQure's score of -0.04 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	8 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Cytokinetics	14 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

uniQure beats Cytokinetics on 10 of the 17 factors compared between the two stocks.

Get uniQure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QURE vs. The Competition

Export

Metric	uniQure	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.03B	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-10.88	7.38	282.28	24.66
Price / Sales	187.99	1,199.83	563.21	75.35
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	13.68	16.96	10.96	6.07
Net Income	-$198.97M	-$12.56M	$3.49B	$347.99M
7 Day Performance	14.18%	-1.80%	-0.63%	-0.44%
1 Month Performance	4.35%	-8.44%	-5.23%	-4.81%
1 Year Performance	218.70%	48.63%	62.07%	18.61%

uniQure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QURE uniQure	3.1968 of 5 stars	$42.83 -1.8%	$65.00 +51.8%	+218.7%	$2.97B	$16.10M	N/A	500	Earnings Report Analyst Downgrade Analyst Revision
MDGL Madrigal Pharmaceuticals	4.1419 of 5 stars	$467.32 -5.2%	$688.20 +47.3%	+54.7%	$11.37B	$958.40M	N/A	90	Earnings Report Analyst Forecast Gap Up High Trading Volume
ABVX Abivax	3.9321 of 5 stars	$124.92 +0.5%	$156.50 +25.3%	+73.6%	$10.85B	N/A	N/A	61	Positive News
KRYS Krystal Biotech	3.2734 of 5 stars	$341.12 -7.0%	$360.67 +5.7%	+117.3%	$10.81B	$389.13M	45.60	210	News Coverage Positive News Earnings Report Gap Up
SMMT Summit Therapeutics	3.4832 of 5 stars	$13.02 -3.1%	$26.15 +100.9%	-51.9%	$10.72B	N/A	N/A	110	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QURE) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

uniQure (QURE) Competitors

QURE vs. MDGL, ABVX, KRYS, SMMT, and CYTK

How does uniQure compare to Madrigal Pharmaceuticals?

Summary

How does uniQure compare to Abivax?

Summary

How does uniQure compare to Krystal Biotech?

Summary

How does uniQure compare to Summit Therapeutics?

Summary

How does uniQure compare to Cytokinetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

uniQure (QURE) Competitors

QURE vs. MDGL, ABVX, KRYS, SMMT, and CYTK

How does uniQure compare to Madrigal Pharmaceuticals?

Which has more volatility and risk, MDGL or QURE?

Do analysts recommend MDGL or QURE?

Which has higher valuation & earnings, MDGL or QURE?

Do institutionals and insiders believe in MDGL or QURE?

Does the media refer more to MDGL or QURE?

Is MDGL or QURE more profitable?

Summary

How does uniQure compare to Abivax?

Does the media favor QURE or ABVX?

Which has more volatility & risk, QURE or ABVX?

Is QURE or ABVX more profitable?

Do analysts prefer QURE or ABVX?

Do institutionals & insiders have more ownership in QURE or ABVX?

Which has higher valuation & earnings, QURE or ABVX?

Summary

How does uniQure compare to Krystal Biotech?

Do institutionals and insiders have more ownership in QURE or KRYS?

Which has preferable valuation and earnings, QURE or KRYS?

Is QURE or KRYS more profitable?

Does the media prefer QURE or KRYS?

Do analysts recommend QURE or KRYS?

Which has more risk & volatility, QURE or KRYS?

Summary

How does uniQure compare to Summit Therapeutics?

Do analysts rate SMMT or QURE?

Do insiders and institutionals have more ownership in SMMT or QURE?

Does the media favor SMMT or QURE?

Which has more volatility and risk, SMMT or QURE?

Which has better valuation and earnings, SMMT or QURE?

Is SMMT or QURE more profitable?

Summary

How does uniQure compare to Cytokinetics?

Do institutionals and insiders have more ownership in QURE or CYTK?

Do analysts prefer QURE or CYTK?

Which has stronger earnings & valuation, QURE or CYTK?

Is QURE or CYTK more profitable?

Which has more risk & volatility, QURE or CYTK?

Does the media favor QURE or CYTK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools